Valneva successfully completes pivotal phase 3 trial of single-shot chikungunya vaccine candidate

Saint herblain ( france), march 8 , 2022 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced the successful completion of the phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, vla1553. the positive final analysis included six-month follow-up data and confirmed the topline results reported in august 2021. valneva now expects to commence the pre-submission process with the u.s. food and drug administration (fda) in the second quarter of 2022.
VALN Ratings Summary
VALN Quant Ranking